Genetics of long-term treatment outcome in bipolar disorder.
Bologna, Italy. In Prog Neuropsychopharmacol Biol Psychiatry, Sep 2015
Genes previously involved in the susceptibility to BD (DFNB31, SORCS2, NRXN1, CNTNAP2, GRIN2A, GRM4, GRIN2B), antidepressant action (DEPTOR, CHRNA7, NRXN1), and mood stabilizer or antipsychotic action (NTRK2, CHRNA7, NRXN1) may affect long-term treatment outcome of BD.
Targeted next generation sequencing for molecular diagnosis of Usher syndrome.
Valencia, Spain. In Orphanet J Rare Dis, 2013
METHODS: A custom HaloPlex panel for Illumina platforms was designed to capture all exons of the 10 known causative Usher syndrome genes (MYO7A, USH1C, CDH23, PCDH15, USH1G, CIB2, USH2A, GPR98, DFNB31 and CLRN1), the two Usher syndrome-related genes (HARS and PDZD7) and the two candidate genes VEZT and MYO15A.
Non-USH2A mutations in USH2 patients.
Montpellier, France. In Hum Mutat, 2012
Mutation found in USH2A, GPR98, or DFNB31 account for the vast majority of USH2 patients and their analysis provide a robust pathway for routine molecular diagnosis.
The role of the MAGUK protein CASK in neural development and synaptic function.
Taipei, Taiwan. In Curr Med Chem, 2005
These proteins, whose interactions with CASK are reviewed here, include the Parkinson's disease molecule parkin, the adhesion molecule neurexin, syndecans, calcium channel proteins, the cytoplasmic adaptor protein Mint1, Veli/mLIN-7/MALS, SAP97, caskin and CIP98, transcription factor Tbr-1, and nucleosome assembly protein CINAP.
Usher Syndrome Type II
Seattle, United States. In Unknown Journal, 2000
Biallelic mutations in one of three genes are known to cause Usher syndrome type II: USH2A (accounting for up to 80% of cases), GPR98 (VLGR1), and DFNB31.